- Home
- ALXO vs NRXP Comparison
ALXO vs NRXP Comparison
Compare ALXO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- NRXP
- Stock Information
- Founded
- ALXO 2015
- NRXP 2015
- Country
- ALXO United States
- NRXP United States
- Employees
- ALXO N/A
- NRXP N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- NRXP Health Care
- Exchange
- ALXO Nasdaq
- NRXP Nasdaq
- Market Cap
- ALXO 56.8M
- NRXP 58.5M
- IPO Year
- ALXO 2020
- NRXP N/A
- Fundamental
- Price
- ALXO $1.05
- NRXP $3.00
- Analyst Decision
- ALXO Strong Buy
- NRXP Strong Buy
- Analyst Count
- ALXO 6
- NRXP 5
- Target Price
- ALXO $3.30
- NRXP $31.40
- AVG Volume (30 Days)
- ALXO 1.7M
- NRXP 536.2K
- Earning Date
- ALXO 11-06-2025
- NRXP 11-13-2025
- Dividend Yield
- ALXO N/A
- NRXP N/A
- EPS Growth
- ALXO N/A
- NRXP N/A
- EPS
- ALXO N/A
- NRXP N/A
- Revenue
- ALXO N/A
- NRXP N/A
- Revenue This Year
- ALXO N/A
- NRXP N/A
- Revenue Next Year
- ALXO N/A
- NRXP $231.16
- P/E Ratio
- ALXO N/A
- NRXP N/A
- Revenue Growth
- ALXO N/A
- NRXP N/A
- 52 Week Low
- ALXO $0.40
- NRXP $1.10
- 52 Week High
- ALXO $2.36
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ALXO 54.14
- NRXP 57.49
- Support Level
- ALXO $1.01
- NRXP $2.73
- Resistance Level
- ALXO $1.27
- NRXP $3.19
- Average True Range (ATR)
- ALXO 0.12
- NRXP 0.25
- MACD
- ALXO -0.02
- NRXP 0.05
- Stochastic Oscillator
- ALXO 29.03
- NRXP 79.66
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.